NHLBI Progenitor Cell Translational Consortium (U01)

 

This Funding Opportunity Announcement requests applications to participate in the NHLBI Progenitor Cell Translational Consortium (PCTC). The goal of the Consortium is to translate advances in progenitor cell biology towards application to heart, lung, and blood diseases. The initiative will focus on the use of progenitor cell-based disease models to understand disease mechanisms, the development of novel therapies, and the application of cell-based therapies for the treatment of diseases.

Active RFA-HL-16-021 Agency: Department of Health and Human Services
Office: National Institutes of Health Cooperative Agreement 5 Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. 02/08/2016 This program does not have cost sharing or matching requirements. NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV
http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-16-021.html FBOWebmaster@OD.NIH.GOV $0.00